Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma
FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated...
Gespeichert in:
| Veröffentlicht in: | Cancer research communications 2024-12, Vol.4 (12), p.3165-3179 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3179 |
|---|---|
| container_issue | 12 |
| container_start_page | 3165 |
| container_title | Cancer research communications |
| container_volume | 4 |
| creator | Zhang, Yichi Ojalill, Marjaana Boyer, Antonia Chen, Xiao Lei Tahon, Elise Thivolle Lioux, Gaëtan Xia, Marvin Abbas, Maryam Soylu, Halime Meryem Flieder, Douglas B Connolly, Denise C Molinolo, Alfredo A McHale, Michael T Stupack, Dwayne G Schlaepfer, David D |
| description | FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type- and context-dependent. |
| doi_str_mv | 10.1158/2767-9764.CRC-24-0382 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3132611851</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3132611851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c187t-9d0d33f4ee9ae26cf1107cdbe6142ffc412442afadce7e6e52a7f5a6b871539c3</originalsourceid><addsrcrecordid>eNpNkMtKw0AUhgdRbKl9BGWWblLnmkmWJVgVixWt6-F0cqIjaVJnEsG3t6W1uDo_h_8CHyGXnE0419mNMKlJcpOqSfFSJEIlTGbihAyP_9N_ekDGMX4yxoQxSqfynAxkrjPNMj0ky6fe1QiBzloHNZ2WHxh929BH30BE-hzaDl0XKbyDb2JHCx83NXS-oa9dwBjpVi2-IXhoaAHB-aZdwwU5q6COOD7cEXmb3S6L-2S-uHsopvPE8cx0SV6yUspKIeaAInUV58y4coUpV6KqnOJCKQEVlA4NpqgFmEpDusoM1zJ3ckSu972b0H71GDu79tFhXUODbR-t5FKknGeab616b3WhjTFgZTfBryH8WM7sjqnd8bI7XnbL1Apld0y3uavDRL9aY3lM_RGUv74EcwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3132611851</pqid></control><display><type>article</type><title>Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Zhang, Yichi ; Ojalill, Marjaana ; Boyer, Antonia ; Chen, Xiao Lei ; Tahon, Elise ; Thivolle Lioux, Gaëtan ; Xia, Marvin ; Abbas, Maryam ; Soylu, Halime Meryem ; Flieder, Douglas B ; Connolly, Denise C ; Molinolo, Alfredo A ; McHale, Michael T ; Stupack, Dwayne G ; Schlaepfer, David D</creator><creatorcontrib>Zhang, Yichi ; Ojalill, Marjaana ; Boyer, Antonia ; Chen, Xiao Lei ; Tahon, Elise ; Thivolle Lioux, Gaëtan ; Xia, Marvin ; Abbas, Maryam ; Soylu, Halime Meryem ; Flieder, Douglas B ; Connolly, Denise C ; Molinolo, Alfredo A ; McHale, Michael T ; Stupack, Dwayne G ; Schlaepfer, David D</creatorcontrib><description>FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type- and context-dependent.</description><identifier>ISSN: 2767-9764</identifier><identifier>EISSN: 2767-9764</identifier><identifier>DOI: 10.1158/2767-9764.CRC-24-0382</identifier><identifier>PMID: 39585085</identifier><language>eng</language><publisher>United States</publisher><subject>Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Cell Line, Tumor ; Cell Nucleus - drug effects ; Cell Nucleus - metabolism ; Cell Survival - drug effects ; Cisplatin - pharmacology ; Female ; Focal Adhesion Kinase 1 - metabolism ; Focal Adhesion Protein-Tyrosine Kinases - antagonists & inhibitors ; Focal Adhesion Protein-Tyrosine Kinases - metabolism ; Humans ; MAP Kinase Signaling System - drug effects ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology</subject><ispartof>Cancer research communications, 2024-12, Vol.4 (12), p.3165-3179</ispartof><rights>2024 The Authors; Published by the American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c187t-9d0d33f4ee9ae26cf1107cdbe6142ffc412442afadce7e6e52a7f5a6b871539c3</cites><orcidid>0009-0003-3726-7243 ; 0000-0003-4814-9210 ; 0009-0008-2716-8280 ; 0000-0001-7998-9963 ; 0009-0008-2712-0922 ; 0000-0002-7422-4213 ; 0000-0003-4396-5745 ; 0009-0002-0136-6162 ; 0000-0003-1088-624X ; 0000-0001-8412-2889 ; 0000-0003-3181-6742 ; 0009-0005-9146-0233 ; 0000-0003-4755-1750 ; 0000-0003-0888-2004 ; 0009-0004-5641-8905</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39585085$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Yichi</creatorcontrib><creatorcontrib>Ojalill, Marjaana</creatorcontrib><creatorcontrib>Boyer, Antonia</creatorcontrib><creatorcontrib>Chen, Xiao Lei</creatorcontrib><creatorcontrib>Tahon, Elise</creatorcontrib><creatorcontrib>Thivolle Lioux, Gaëtan</creatorcontrib><creatorcontrib>Xia, Marvin</creatorcontrib><creatorcontrib>Abbas, Maryam</creatorcontrib><creatorcontrib>Soylu, Halime Meryem</creatorcontrib><creatorcontrib>Flieder, Douglas B</creatorcontrib><creatorcontrib>Connolly, Denise C</creatorcontrib><creatorcontrib>Molinolo, Alfredo A</creatorcontrib><creatorcontrib>McHale, Michael T</creatorcontrib><creatorcontrib>Stupack, Dwayne G</creatorcontrib><creatorcontrib>Schlaepfer, David D</creatorcontrib><title>Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma</title><title>Cancer research communications</title><addtitle>Cancer Res Commun</addtitle><description>FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type- and context-dependent.</description><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cell Line, Tumor</subject><subject>Cell Nucleus - drug effects</subject><subject>Cell Nucleus - metabolism</subject><subject>Cell Survival - drug effects</subject><subject>Cisplatin - pharmacology</subject><subject>Female</subject><subject>Focal Adhesion Kinase 1 - metabolism</subject><subject>Focal Adhesion Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Focal Adhesion Protein-Tyrosine Kinases - metabolism</subject><subject>Humans</subject><subject>MAP Kinase Signaling System - drug effects</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><issn>2767-9764</issn><issn>2767-9764</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkMtKw0AUhgdRbKl9BGWWblLnmkmWJVgVixWt6-F0cqIjaVJnEsG3t6W1uDo_h_8CHyGXnE0419mNMKlJcpOqSfFSJEIlTGbihAyP_9N_ekDGMX4yxoQxSqfynAxkrjPNMj0ky6fe1QiBzloHNZ2WHxh929BH30BE-hzaDl0XKbyDb2JHCx83NXS-oa9dwBjpVi2-IXhoaAHB-aZdwwU5q6COOD7cEXmb3S6L-2S-uHsopvPE8cx0SV6yUspKIeaAInUV58y4coUpV6KqnOJCKQEVlA4NpqgFmEpDusoM1zJ3ckSu972b0H71GDu79tFhXUODbR-t5FKknGeab616b3WhjTFgZTfBryH8WM7sjqnd8bI7XnbL1Apld0y3uavDRL9aY3lM_RGUv74EcwA</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Zhang, Yichi</creator><creator>Ojalill, Marjaana</creator><creator>Boyer, Antonia</creator><creator>Chen, Xiao Lei</creator><creator>Tahon, Elise</creator><creator>Thivolle Lioux, Gaëtan</creator><creator>Xia, Marvin</creator><creator>Abbas, Maryam</creator><creator>Soylu, Halime Meryem</creator><creator>Flieder, Douglas B</creator><creator>Connolly, Denise C</creator><creator>Molinolo, Alfredo A</creator><creator>McHale, Michael T</creator><creator>Stupack, Dwayne G</creator><creator>Schlaepfer, David D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0003-3726-7243</orcidid><orcidid>https://orcid.org/0000-0003-4814-9210</orcidid><orcidid>https://orcid.org/0009-0008-2716-8280</orcidid><orcidid>https://orcid.org/0000-0001-7998-9963</orcidid><orcidid>https://orcid.org/0009-0008-2712-0922</orcidid><orcidid>https://orcid.org/0000-0002-7422-4213</orcidid><orcidid>https://orcid.org/0000-0003-4396-5745</orcidid><orcidid>https://orcid.org/0009-0002-0136-6162</orcidid><orcidid>https://orcid.org/0000-0003-1088-624X</orcidid><orcidid>https://orcid.org/0000-0001-8412-2889</orcidid><orcidid>https://orcid.org/0000-0003-3181-6742</orcidid><orcidid>https://orcid.org/0009-0005-9146-0233</orcidid><orcidid>https://orcid.org/0000-0003-4755-1750</orcidid><orcidid>https://orcid.org/0000-0003-0888-2004</orcidid><orcidid>https://orcid.org/0009-0004-5641-8905</orcidid></search><sort><creationdate>20241201</creationdate><title>Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma</title><author>Zhang, Yichi ; Ojalill, Marjaana ; Boyer, Antonia ; Chen, Xiao Lei ; Tahon, Elise ; Thivolle Lioux, Gaëtan ; Xia, Marvin ; Abbas, Maryam ; Soylu, Halime Meryem ; Flieder, Douglas B ; Connolly, Denise C ; Molinolo, Alfredo A ; McHale, Michael T ; Stupack, Dwayne G ; Schlaepfer, David D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c187t-9d0d33f4ee9ae26cf1107cdbe6142ffc412442afadce7e6e52a7f5a6b871539c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cell Line, Tumor</topic><topic>Cell Nucleus - drug effects</topic><topic>Cell Nucleus - metabolism</topic><topic>Cell Survival - drug effects</topic><topic>Cisplatin - pharmacology</topic><topic>Female</topic><topic>Focal Adhesion Kinase 1 - metabolism</topic><topic>Focal Adhesion Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Focal Adhesion Protein-Tyrosine Kinases - metabolism</topic><topic>Humans</topic><topic>MAP Kinase Signaling System - drug effects</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Yichi</creatorcontrib><creatorcontrib>Ojalill, Marjaana</creatorcontrib><creatorcontrib>Boyer, Antonia</creatorcontrib><creatorcontrib>Chen, Xiao Lei</creatorcontrib><creatorcontrib>Tahon, Elise</creatorcontrib><creatorcontrib>Thivolle Lioux, Gaëtan</creatorcontrib><creatorcontrib>Xia, Marvin</creatorcontrib><creatorcontrib>Abbas, Maryam</creatorcontrib><creatorcontrib>Soylu, Halime Meryem</creatorcontrib><creatorcontrib>Flieder, Douglas B</creatorcontrib><creatorcontrib>Connolly, Denise C</creatorcontrib><creatorcontrib>Molinolo, Alfredo A</creatorcontrib><creatorcontrib>McHale, Michael T</creatorcontrib><creatorcontrib>Stupack, Dwayne G</creatorcontrib><creatorcontrib>Schlaepfer, David D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Yichi</au><au>Ojalill, Marjaana</au><au>Boyer, Antonia</au><au>Chen, Xiao Lei</au><au>Tahon, Elise</au><au>Thivolle Lioux, Gaëtan</au><au>Xia, Marvin</au><au>Abbas, Maryam</au><au>Soylu, Halime Meryem</au><au>Flieder, Douglas B</au><au>Connolly, Denise C</au><au>Molinolo, Alfredo A</au><au>McHale, Michael T</au><au>Stupack, Dwayne G</au><au>Schlaepfer, David D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma</atitle><jtitle>Cancer research communications</jtitle><addtitle>Cancer Res Commun</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>4</volume><issue>12</issue><spage>3165</spage><epage>3179</epage><pages>3165-3179</pages><issn>2767-9764</issn><eissn>2767-9764</eissn><abstract>FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type- and context-dependent.</abstract><cop>United States</cop><pmid>39585085</pmid><doi>10.1158/2767-9764.CRC-24-0382</doi><tpages>15</tpages><orcidid>https://orcid.org/0009-0003-3726-7243</orcidid><orcidid>https://orcid.org/0000-0003-4814-9210</orcidid><orcidid>https://orcid.org/0009-0008-2716-8280</orcidid><orcidid>https://orcid.org/0000-0001-7998-9963</orcidid><orcidid>https://orcid.org/0009-0008-2712-0922</orcidid><orcidid>https://orcid.org/0000-0002-7422-4213</orcidid><orcidid>https://orcid.org/0000-0003-4396-5745</orcidid><orcidid>https://orcid.org/0009-0002-0136-6162</orcidid><orcidid>https://orcid.org/0000-0003-1088-624X</orcidid><orcidid>https://orcid.org/0000-0001-8412-2889</orcidid><orcidid>https://orcid.org/0000-0003-3181-6742</orcidid><orcidid>https://orcid.org/0009-0005-9146-0233</orcidid><orcidid>https://orcid.org/0000-0003-4755-1750</orcidid><orcidid>https://orcid.org/0000-0003-0888-2004</orcidid><orcidid>https://orcid.org/0009-0004-5641-8905</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2767-9764 |
| ispartof | Cancer research communications, 2024-12, Vol.4 (12), p.3165-3179 |
| issn | 2767-9764 2767-9764 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3132611851 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cell Line, Tumor Cell Nucleus - drug effects Cell Nucleus - metabolism Cell Survival - drug effects Cisplatin - pharmacology Female Focal Adhesion Kinase 1 - metabolism Focal Adhesion Protein-Tyrosine Kinases - antagonists & inhibitors Focal Adhesion Protein-Tyrosine Kinases - metabolism Humans MAP Kinase Signaling System - drug effects Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology |
| title | Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T21%3A39%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nuclear%20Focal%20Adhesion%20Kinase%20Protects%20against%20Cisplatin%20Stress%20in%20Ovarian%20Carcinoma&rft.jtitle=Cancer%20research%20communications&rft.au=Zhang,%20Yichi&rft.date=2024-12-01&rft.volume=4&rft.issue=12&rft.spage=3165&rft.epage=3179&rft.pages=3165-3179&rft.issn=2767-9764&rft.eissn=2767-9764&rft_id=info:doi/10.1158/2767-9764.CRC-24-0382&rft_dat=%3Cproquest_cross%3E3132611851%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3132611851&rft_id=info:pmid/39585085&rfr_iscdi=true |